APO Research
Talk to an analyst

APO RESEARCH · REPORT

Autologous Stem Cell & Non-stem Cell Therapies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Autologous Stem Cell & Non-stem Cell Therapies Market Outlook and Growth Opportunities 2026

3 May 2026190 pages

Choose your research edition.

Industry ResearchAutologous Stem Cell & Non-stem Cell Therapies Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Autologous Stem Cell & Non-stem Cell Therapies Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Autologous Stem Cell & Non-stem Cell Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Autologous Stem Cell & Non-stem Cell Therapies Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Autologous Stem Cell & Non-stem Cell Therapies Market Analysis and Forecast 2026-2032183 pages · $4,950 USD

Market perspective

The global Autologous Stem Cell & Non-stem Cell Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Autologous Stem Cell & Non-stem Cell Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Autologous Stem Cell & Non-stem Cell Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Autologous Stem Cell & Non-stem Cell Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Autologous Stem Cell & Non-stem Cell Therapies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Autologous Stem Cell & Non-stem Cell Therapies market include Anterogen Co., Ltd., APAC Biotech, Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.), Gilead Sciences, Inc., Green Cross Holdings Co., Ltd. (GC Cell), Healiva SA and ImmunoACT, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Autologous Stem Cell & Non-stem Cell Therapies market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Autologous Stem Cell & Non-stem Cell Therapies and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Autologous Stem Cell & Non-stem Cell Therapies revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Autologous Stem Cell & Non-stem Cell Therapies market.

Autologous Stem Cell & Non-stem Cell Therapies Segment by Company

Anterogen Co., Ltd.

APAC Biotech

Bristol-Myers Squibb Company

CARsgen Therapeutics Holdings Limited

Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)

Gilead Sciences, Inc.

Green Cross Holdings Co., Ltd. (GC Cell)

Healiva SA

ImmunoACT

Iaso Biotherapeutics

Johnson & Johnson

Lovance Biotherapeutics, Inc.

Novartis AG

Pharmicell Co., Ltd.

Regrow Biosciences Pvt Ltd.

Tegoscience

Vericel Corporation

W (Cayman) Therapeutics Co. Ltd.

Autologous Stem Cell & Non-stem Cell Therapies Segment by Type

CAR-T

Tumor Infiltrating Lymphocyte

Autologous Stem Cell & Non-stem Cell Therapies Segment by Application

Hospital

Surgery Center

Other

Autologous Stem Cell & Non-stem Cell Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Autologous Stem Cell & Non-stem Cell Therapies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Autologous Stem Cell & Non-stem Cell Therapies key companies, revenue, market share, and recent developments.

3. To split the Autologous Stem Cell & Non-stem Cell Therapies breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Autologous Stem Cell & Non-stem Cell Therapies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Autologous Stem Cell & Non-stem Cell Therapies significant trends, drivers, influence factors in global and regions.

6. To analyze Autologous Stem Cell & Non-stem Cell Therapies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Autologous Stem Cell & Non-stem Cell Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Autologous Stem Cell & Non-stem Cell Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Autologous Stem Cell & Non-stem Cell Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Autologous Stem Cell & Non-stem Cell Therapies industry.

Chapter 3: Detailed analysis of Autologous Stem Cell & Non-stem Cell Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Autologous Stem Cell & Non-stem Cell Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Autologous Stem Cell & Non-stem Cell Therapies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Autologous Stem Cell & Non-stem Cell Therapies Industry Trends Table 2. Autologous Stem Cell & Non-stem Cell Therapies Industry Drivers Table 3. Autologous Stem Cell & Non-stem Cell Therapies Industry Opportunities and Challenges Table 4. Autologous Stem Cell & Non-stem Cell Therapies Industry Restraints Table 5. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Company (2021-2026) Table 7. Global Autologous Stem Cell & Non-stem Cell Therapies Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Autologous Stem Cell & Non-stem Cell Therapies Key Company Manufacturing Base & Headquarters Table 9. Global Autologous Stem Cell & Non-stem Cell Therapies Company, Product Type & Application Table 10. Global Autologous Stem Cell & Non-stem Cell Therapies Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Autologous Stem Cell & Non-stem Cell Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CAR-T Table 15. Significant Companies of Tumor Infiltrating Lymphocyte Table 16. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type (2021-2026) Table 20. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Surgery Center Table 23. Significant Companies of Other Table 24. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application (2021-2026) Table 28. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application (2027-2032) Table 29. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Region (2021-2026) Table 32. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Region (2027-2032) Table 34. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Market Share by Country (2021-2026) Table 37. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Market Share by Country (2027-2032) Table 39. Anterogen Co., Ltd. Company Information Table 40. Anterogen Co., Ltd. Business Overview Table 41. Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 43. Anterogen Co., Ltd. Recent Development Table 44. APAC Biotech Company Information Table 45. APAC Biotech Business Overview Table 46. APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 48. APAC Biotech Recent Development Table 49. Bristol-Myers Squibb Company Company Information Table 50. Bristol-Myers Squibb Company Business Overview Table 51. Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 53. Bristol-Myers Squibb Company Recent Development Table 54. CARsgen Therapeutics Holdings Limited Company Information Table 55. CARsgen Therapeutics Holdings Limited Business Overview Table 56. CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 58. CARsgen Therapeutics Holdings Limited Recent Development Table 59. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Company Information Table 60. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Business Overview Table 61. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 63. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Recent Development Table 64. Gilead Sciences, Inc. Company Information Table 65. Gilead Sciences, Inc. Business Overview Table 66. Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 68. Gilead Sciences, Inc. Recent Development Table 69. Green Cross Holdings Co., Ltd. (GC Cell) Company Information Table 70. Green Cross Holdings Co., Ltd. (GC Cell) Business Overview Table 71. Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 73. Green Cross Holdings Co., Ltd. (GC Cell) Recent Development Table 74. Healiva SA Company Information Table 75. Healiva SA Business Overview Table 76. Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 78. Healiva SA Recent Development Table 79. ImmunoACT Company Information Table 80. ImmunoACT Business Overview Table 81. ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 83. ImmunoACT Recent Development Table 84. Iaso Biotherapeutics Company Information Table 85. Iaso Biotherapeutics Business Overview Table 86. Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 88. Iaso Biotherapeutics Recent Development Table 89. Johnson & Johnson Company Information Table 90. Johnson & Johnson Business Overview Table 91. Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 93. Johnson & Johnson Recent Development Table 94. Lovance Biotherapeutics, Inc. Company Information Table 95. Lovance Biotherapeutics, Inc. Business Overview Table 96. Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 98. Lovance Biotherapeutics, Inc. Recent Development Table 99. Novartis AG Company Information Table 100. Novartis AG Business Overview Table 101. Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 103. Novartis AG Recent Development Table 104. Pharmicell Co., Ltd. Company Information Table 105. Pharmicell Co., Ltd. Business Overview Table 106. Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 108. Pharmicell Co., Ltd. Recent Development Table 109. Regrow Biosciences Pvt Ltd. Company Information Table 110. Regrow Biosciences Pvt Ltd. Business Overview Table 111. Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 113. Regrow Biosciences Pvt Ltd. Recent Development Table 114. Tegoscience Company Information Table 115. Tegoscience Business Overview Table 116. Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 118. Tegoscience Recent Development Table 119. Vericel Corporation Company Information Table 120. Vericel Corporation Business Overview Table 121. Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 123. Vericel Corporation Recent Development Table 124. W (Cayman) Therapeutics Co. Ltd. Company Information Table 125. W (Cayman) Therapeutics Co. Ltd. Business Overview Table 126. W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 128. W (Cayman) Therapeutics Co. Ltd. Recent Development Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Autologous Stem Cell & Non-stem Cell Therapies Product Image Figure 2. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size (2021-2032) & (US$ Million) Figure 4. Global Autologous Stem Cell & Non-stem Cell Therapies Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CAR-T Image Figure 8. Tumor Infiltrating Lymphocyte Image Figure 9. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Surgery Center Image Figure 14. Other Image Figure 15. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application (2021-2032) Figure 18. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032) & (US$ Million) Figure 21. North America Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032) & (US$ Million) Figure 27. South America Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T
  • Tumor Infiltrating Lymphocyte
Applications
  • Hospital
  • Surgery Center
  • Other
Companies covered
  • Anterogen Co., Ltd.
  • APAC Biotech
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics Holdings Limited
  • Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
  • Gilead Sciences, Inc.
  • Green Cross Holdings Co., Ltd. (GC Cell)
  • Healiva SA
  • ImmunoACT
  • Iaso Biotherapeutics
  • Johnson & Johnson
  • Lovance Biotherapeutics, Inc.
  • Novartis AG
  • Pharmicell Co., Ltd.
  • Regrow Biosciences Pvt Ltd.
  • Tegoscience
  • Vericel Corporation
  • W (Cayman) Therapeutics Co. Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Autologous Stem Cell & Non-stem Cell Therapies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Autologous Stem Cell & Non-stem Cell Therapies Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Autologous Stem Cell & Non-stem Cell Therapies Market Dynamics
  1. 2.1 Autologous Stem Cell & Non-stem Cell Therapies Industry Trends
  2. 2.2 Autologous Stem Cell & Non-stem Cell Therapies Industry Drivers
  3. 2.3 Autologous Stem Cell & Non-stem Cell Therapies Industry Opportunities and Challenges
  4. 2.4 Autologous Stem Cell & Non-stem Cell Therapies Industry Restraints
3 Autologous Stem Cell & Non-stem Cell Therapies Market by Company
  1. 3.1 Global Autologous Stem Cell & Non-stem Cell Therapies Company Revenue Ranking in 2025
  2. 3.2 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Company (2021-2026)
  3. 3.3 Global Autologous Stem Cell & Non-stem Cell Therapies Company Ranking (2024-2026)
  4. 3.4 Global Autologous Stem Cell & Non-stem Cell Therapies Company Manufacturing Base and Headquarters
  5. 3.5 Global Autologous Stem Cell & Non-stem Cell Therapies Company Product Type and Application
  6. 3.6 Global Autologous Stem Cell & Non-stem Cell Therapies Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Autologous Stem Cell & Non-stem Cell Therapies Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Autologous Stem Cell & Non-stem Cell Therapies Market by Type
  1. 4.1 Autologous Stem Cell & Non-stem Cell Therapies Type Introduction
  2. 4.1.1 CAR-T
  3. 4.1.2 Tumor Infiltrating Lymphocyte
  4. 4.2 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Type
  5. 4.2.1 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Type (2021-2032)
  7. 4.2.3 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type (2021-2032)
5 Autologous Stem Cell & Non-stem Cell Therapies Market by Application
  1. 5.1 Autologous Stem Cell & Non-stem Cell Therapies Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Surgery Center
  4. 5.1.3 Other
  5. 5.2 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Application
  6. 5.2.1 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Application (2021-2032)
  8. 5.2.3 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application (2021-2032)
6 Autologous Stem Cell & Non-stem Cell Therapies Regional Value Analysis
  1. 6.1 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Region (2021-2032)
  3. 6.2.1 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Region: 2021-2026
  4. 6.2.2 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032)
  7. 6.3.2 North America Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032)
  10. 6.4.2 Europe Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032)
  16. 6.6.2 South America Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Country, 2025 VS 2032
7 Autologous Stem Cell & Non-stem Cell Therapies Country-level Value Analysis
  1. 7.1 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Country (2021-2032)
  3. 7.2.1 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Country (2021-2026)
  4. 7.2.2 Global Autologous Stem Cell & Non-stem Cell Therapies Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Autologous Stem Cell & Non-stem Cell Therapies Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Autologous Stem Cell & Non-stem Cell Therapies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Anterogen Co., Ltd.
  2. 8.1.1 Anterogen Co., Ltd. Company Information
  3. 8.1.2 Anterogen Co., Ltd. Business Overview
  4. 8.1.3 Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  6. 8.1.5 Anterogen Co., Ltd. Recent Developments
  7. 8.2 APAC Biotech
  8. 8.2.1 APAC Biotech Company Information
  9. 8.2.2 APAC Biotech Business Overview
  10. 8.2.3 APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  11. 8.2.4 APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  12. 8.2.5 APAC Biotech Recent Developments
  13. 8.3 Bristol-Myers Squibb Company
  14. 8.3.1 Bristol-Myers Squibb Company Company Information
  15. 8.3.2 Bristol-Myers Squibb Company Business Overview
  16. 8.3.3 Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 8.4 CARsgen Therapeutics Holdings Limited
  20. 8.4.1 CARsgen Therapeutics Holdings Limited Company Information
  21. 8.4.2 CARsgen Therapeutics Holdings Limited Business Overview
  22. 8.4.3 CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  24. 8.4.5 CARsgen Therapeutics Holdings Limited Recent Developments
  25. 8.5 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
  26. 8.5.1 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Company Information
  27. 8.5.2 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Business Overview
  28. 8.5.3 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  30. 8.5.5 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Recent Developments
  31. 8.6 Gilead Sciences, Inc.
  32. 8.6.1 Gilead Sciences, Inc. Company Information
  33. 8.6.2 Gilead Sciences, Inc. Business Overview
  34. 8.6.3 Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  36. 8.6.5 Gilead Sciences, Inc. Recent Developments
  37. 8.7 Green Cross Holdings Co., Ltd. (GC Cell)
  38. 8.7.1 Green Cross Holdings Co., Ltd. (GC Cell) Company Information
  39. 8.7.2 Green Cross Holdings Co., Ltd. (GC Cell) Business Overview
  40. 8.7.3 Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  42. 8.7.5 Green Cross Holdings Co., Ltd. (GC Cell) Recent Developments
  43. 8.8 Healiva SA
  44. 8.8.1 Healiva SA Company Information
  45. 8.8.2 Healiva SA Business Overview
  46. 8.8.3 Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  48. 8.8.5 Healiva SA Recent Developments
  49. 8.9 ImmunoACT
  50. 8.9.1 ImmunoACT Company Information
  51. 8.9.2 ImmunoACT Business Overview
  52. 8.9.3 ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  54. 8.9.5 ImmunoACT Recent Developments
  55. 8.10 Iaso Biotherapeutics
  56. 8.10.1 Iaso Biotherapeutics Company Information
  57. 8.10.2 Iaso Biotherapeutics Business Overview
  58. 8.10.3 Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  60. 8.10.5 Iaso Biotherapeutics Recent Developments
  61. 8.11 Johnson & Johnson
  62. 8.11.1 Johnson & Johnson Company Information
  63. 8.11.2 Johnson & Johnson Business Overview
  64. 8.11.3 Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  66. 8.11.5 Johnson & Johnson Recent Developments
  67. 8.12 Lovance Biotherapeutics, Inc.
  68. 8.12.1 Lovance Biotherapeutics, Inc. Company Information
  69. 8.12.2 Lovance Biotherapeutics, Inc. Business Overview
  70. 8.12.3 Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  72. 8.12.5 Lovance Biotherapeutics, Inc. Recent Developments
  73. 8.13 Novartis AG
  74. 8.13.1 Novartis AG Company Information
  75. 8.13.2 Novartis AG Business Overview
  76. 8.13.3 Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  78. 8.13.5 Novartis AG Recent Developments
  79. 8.14 Pharmicell Co., Ltd.
  80. 8.14.1 Pharmicell Co., Ltd. Company Information
  81. 8.14.2 Pharmicell Co., Ltd. Business Overview
  82. 8.14.3 Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  84. 8.14.5 Pharmicell Co., Ltd. Recent Developments
  85. 8.15 Regrow Biosciences Pvt Ltd.
  86. 8.15.1 Regrow Biosciences Pvt Ltd. Company Information
  87. 8.15.2 Regrow Biosciences Pvt Ltd. Business Overview
  88. 8.15.3 Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  90. 8.15.5 Regrow Biosciences Pvt Ltd. Recent Developments
  91. 8.16 Tegoscience
  92. 8.16.1 Tegoscience Company Information
  93. 8.16.2 Tegoscience Business Overview
  94. 8.16.3 Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  96. 8.16.5 Tegoscience Recent Developments
  97. 8.17 Vericel Corporation
  98. 8.17.1 Vericel Corporation Company Information
  99. 8.17.2 Vericel Corporation Business Overview
  100. 8.17.3 Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  102. 8.17.5 Vericel Corporation Recent Developments
  103. 8.18 W (Cayman) Therapeutics Co. Ltd.
  104. 8.18.1 W (Cayman) Therapeutics Co. Ltd. Company Information
  105. 8.18.2 W (Cayman) Therapeutics Co. Ltd. Business Overview
  106. 8.18.3 W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  107. 8.18.4 W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  108. 8.18.5 W (Cayman) Therapeutics Co. Ltd. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst